R. L. Dow

发表

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

J. Hanke, P. Changelian, J. Gardner, 1996, The Journal of Biological Chemistry.

Progress towards selective inhibition of protein kinase C

R. L. Dow, 1994 .

Undesired versus designed enzymatic cleavage of linkers for liver targeting.

J. Bauman, T. Goosen, R. L. Dow, 2014, Bioorganic & medicinal chemistry letters.

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

M. Ammirati, A. Carlo, A. Mathiowetz, 2015, ACS medicinal chemistry letters.

Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase (ACC) Inhibitors Through Liver Targeting.

David A. Price, A. Kalgutkar, S. Liras, 2020, Journal of medicinal chemistry.

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

L. Buckbinder, K. Stone, Adam G Schwaid, 2015, ACS chemical biology.

High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid.

M. G. Finn, M. Varma, R. L. Dow, 2013, Current topics in medicinal chemistry.

Chapter 17. Recent Advancements in the Discovery and Development of Agents for the Treatment of Diabetes.

R. L. Dow, D. Kreutter, 1995 .

Overview: Diabetes: New Chemical Entities

R. L. Dow, D. Clark, 1992 .

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

D. Scott, D. Hargrove, R. L. Dow, 2010, Biochemical and biophysical research communications.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

D. Scott, P. Iredale, S. Sakya, 2006, Bioorganic & medicinal chemistry letters.

Thyroid receptor agonists for the treatment of androgenetic alopecia.

R. L. Dow, J. Li, L. Mitchell, 2010, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.

M. Munchhof, J. Litchfield, K. Karki, 2011, Bioorganic & medicinal chemistry letters.

Total synthesis and stereochemical assignment of (±)-Epiderstatin

J. Lowe, R. L. Dow, M. A. Hain, 1992 .

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

D. Scott, P. Iredale, Xingrong Liu, 2010, BMC pharmacology.

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

D. Scott, P. Iredale, C. Nduaka, 2009, Journal of medicinal chemistry.

Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.

T. Maurer, D. Hargrove, R. L. Dow, 2004, Bioorganic & medicinal chemistry letters.

Total Synthesis of the Polyether Antibiotic Ionomycin

Davidr . Evans, R. L. Dow, J. M. Takacs, 1990 .

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.

D. Scott, P. Iredale, R. L. Dow, 2012, ACS medicinal chemistry letters.

Aldol addition reactions of chiral crotonate imides

Davidr . Evans, R. L. Dow, J. Bartrolí, 1986 .

Hydroxyl-directed hydrogenation of homoallylic alcohols. Effects of achiral and chiral rhodium catalysts on 1,3 stereocontrol.

Davidr . Evans, R. L. Dow, M. MorrisseyMichael, 1985 .

An efficient synthesis of ethyl 5-oxazoleacetates

R. L. Dow, 1990 .

A Direct Alcohol for Hydrazine Interchange: Scope and Stereochemistry

R. Kelly, R. L. Dow, W. Wierenga, 1981 .

Total synthesis of the ionophore antibiotic ionomycin. Asymmetric synthesis of the C1-C10 and C11-C16 synthons

Davidr . Evans, R. L. Dow, 1986 .

A synthesis of functionalized indoline 2,2-biscarboxylates

S. Wright, D. Hageman, L. D. Mcclure, 1996 .

Medicinal chemistry design principles for liver targeting through OATP transporters.

A. Mathiowetz, S. Liras, J. Pfefferkorn, 2013, Current topics in medicinal chemistry.

PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.

Roger M. Howard, S. Liras, K. Beaumont, 2020, Journal of medicinal chemistry.

β3-adrenergic agonists: potential therapeutics for obesity

R. L. Dow, 1997 .

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

M. Ammirati, L. Buckbinder, A. El‐Kattan, 2018, Journal of medicinal chemistry.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Mechanism-Based Approaches to Cancer Drug Discovery

P. Miller, R. L. Dow, P. Fischer, 1992 .

Synthesis of t-Boc-4-Dimethylphosphonomethyl-L-Phenylalanine1

R. L. Dow, B. M. Bechle, 1994 .

Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors.

T. T. Chou, R. L. Dow, E. R. Larson, 1994, Journal of medicinal chemistry.

Synthesis of tert-Boc-4-dimethylphosphonomethyl-L-phenylalanine (IV).

R. L. Dow, B. M. Bechle, 1995 .

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

D. Scott, P. Iredale, R. L. Dow, 2009, Bioorganic & medicinal chemistry letters.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.

K. Gajiwala, M. Hickey, J. Pfefferkorn, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Margaret S. Landis, D. Scott, P. Iredale, 2009, Journal of medicinal chemistry.

Total synthesis of erbstatin.

R. L. Dow, M. J. Flynn, 1987 .

Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.

Angel Guzman-Perez, Dawn Mather, W. Zavadoski, 2013, Bioorganic & medicinal chemistry.

Synthesis of [19-3H] herbimycin A

R. L. Dow, B. M. Bechle, R. Roth, 1992 .

Steric selectivity in oxidations of diols

V. Bagheri, R. L. Dow, M. Doyle, 1980 .

Selective Oxidations of Alcohols by Bromine in Combination with Nickel(II) Benzoate

R. L. Dow, M. Doyle, 1981 .

Efficient Synthesis of 4-Amino-2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidin-5-ones: Practical Access to a Novel Chemotype in the Development of DGAT-1 Inhibitors

M. Munchhof, K. Karki, R. L. Dow, 2012, Synthesis.

Selective inhibition of the tyrosine kinase pp60src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one

T. T. Chou, R. L. Dow, B. M. Bechle, 1995 .

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents.

T. T. Chou, R. L. Dow, R. W. Stevenson, 1991, Journal of medicinal chemistry.

Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.

A. Mathiowetz, D. Beebe, R. L. Dow, 2013, Journal of medicinal chemistry.

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.

Peter Cornelius, Eunsun Lee, Dennis E Danley, 2003, Bioorganic & medicinal chemistry letters.